Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Melanoma and other skin tumours

4008 - Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts

Date

28 Sep 2019

Session

Poster Discussion – Melanoma and other skin tumours

Presenters

Krisztian Homicsko

Citation

Annals of Oncology (2019) 30 (suppl_5): v533-v563. 10.1093/annonc/mdz255

Authors

K. Homicsko1, D. Barras1, V. Aedo Lopez2, B. Gautron Moura3, G. Berthod4, M. Matter5, O. Gaide6, G. Coukos7, D. Hanahan8, O.A. Michielin3

Author affiliations

  • 1 Oncology, CHUV, 1011 - Lausanne/CH
  • 2 Oncology, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 3 Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 4 Oncology, Hôpital Régional Sion-Hérens-Conthey, Site de Champsec Centre du Cancer Lausanne, 1951 - Sion/CH
  • 5 Visceral Surgery, CHUV, 1011 - Lausanne/CH
  • 6 Dermatology, CHUV, 1011 - Lausanne/CH
  • 7 Oncology, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), 1066 - Epalinges/CH
  • 8 Isrec, Swiss Institute of Experimental Cancer Research, EPFL, 1010 - Lausanne/CH

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4008

Background

Single cell transcriptomic analyses of the tumor microenvironment provides unprecedented opportunities to guide precision immune therapy of melanoma patients. Previous single-cell RNA sequencing studies in metastatic melanoma patients have shown that the TME composition can be deciphered with a FACS-based single cell assay. Here, we applied droplet-based single-cell RNA sequencing for the decomposition of the tumor microenvironment of metastatic melanoma patients before PD1-based immune therapies and, when possible, during or after PD1 therapy.

Methods

Fresh biopsies and surgical excisions from melanoma patients destined for standard-of-care immune therapy were collected and processed within 2 hours. To capture the global cell composition, cells were not FACS sorted. We performed single-cell RNA sequencing using the 10x Chromium platform. We used both 3’ and 5’ RNA sequencing. Libraries were sequenced at the Campus Biotech platform in Geneva. Standard analytical pipelines were applied (Cell Ranger 3.0, Seurat 2.0).

Results

Our current dataset comprises a total of 26 tumors from 18 patients with a total number of 66’923 cells. The mean number of cells analyzed per patient was 2573 (Range: 160-12’676). Immune TME cell types could be readily identified, but with a significant patient-to-patient heterogeneity. Importantly, melanoma-associated fibroblasts (MAFs) were observed in most tumors (23/26), with an abundance of > 1% in 19 out of 26 tumors. The MAF population, which in total comprised 4722 cells (median 2.1%/tumor, range: 0-59.8%) was heterogeneous and was composed of at least two different sub-clusters. The MAF subtypes were correlated with outcomes from PD1 therapy, with an immune evasion gene signature, and with bulk TCGA melanoma data, as will be presented.

Conclusions

Unsorted single-cell RNA sequencing of fresh human melanoma samples demonstrably provides an insightful snapshot of heterotypic cell compositions. In contrast to previous FACS-based scRNAseq assays, both immune and non-immune components of the tumor microenvironment are efficiently captured. MAFs form a sizeable and heterogenous component of melanoma tumors, heretofore underappreciated in melanoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

CHUV.

Funding

SystemsX.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.